Synacthen 250mcg Injection

Synacthen 250 mcg Injection contains tetracosactide, a synthetic analogue of adrenocorticotropic hormone (ACTH). It stimulates the adrenal cortex to produce corticosteroid hormones, including cortisol, allowing healthcare professionals to assess adrenal gland function.

The short-acting Synacthen injection is used as a diagnostic aid in the investigation of suspected adrenal insufficiency. It is commonly used in an ACTH stimulation test, in which cortisol levels are measured before and after administration.

Synacthen is a prescription medicine intended for use under appropriate medical supervision. The standard short-acting ampoule must not be confused with Synacthen Depot, which is a different formulation with different product instructions.

Product Information

Product Name

Synacthen Injection

Active Ingredient

Tetracosactide (also known as tetracosactrin)

Strength

250 micrograms/mL

Typical Ampoule Volume

1 mL

Total Content per 1 mL Ampoule

250 micrograms

Dosage Form

Sterile solution for injection

Drug Class

Synthetic ACTH analogue

Primary Indication

Diagnostic investigation of adrenal insufficiency

Route of Administration

Intramuscular or intravenous, according to the relevant product label and diagnostic protocol

Pack Size

Confirm whether the supplier offers single-ampoule or multipack packaging

Prescription Requirement

Subject to local regulations

Ordering and Availability

For Synacthen 250 mcg injection pricing, ampoule sizes and availability, contact the supplier to confirm the exact product, manufacturer, current stock and cold-chain shipping arrangements.

Availability, prescription requirements and regulatory authorization differ by country. Confirm that the product is authorized for the intended use in the destination market and that refrigeration can be maintained throughout storage and transport.

Synacthen 250 mcg Injection may be used by healthcare professionals for:

• Assessment of Adrenal Function: Helps evaluate how the adrenal glands respond to ACTH stimulation.
• Investigation of Adrenal Insufficiency: Supports the diagnostic assessment of suspected inadequate adrenal hormone production.
• Cortisol Response Testing: Stimulates cortisol production so that blood samples can be assessed at specified intervals.

The results must be interpreted by a qualified healthcare professional alongside the patient's medical history, laboratory findings and applicable diagnostic criteria.

Synacthen 250 mcg Injection should be administered only by qualified healthcare professionals according to the approved product instructions and the diagnostic protocol.

A commonly used adult short Synacthen test involves a single 250-microgram dose, with cortisol measurements taken before administration and at a specified interval afterwards. The route, sampling schedule and interpretation must follow the applicable clinical protocol.

Do not self-administer this medicine or use it for repeated treatment unless a specialist and the specific product authorization explicitly direct otherwise. The short-acting Synacthen ampoule is intended for diagnostic use in the referenced UK product information.

Storage Instructions

Store Synacthen according to the exact manufacturer's instructions. The referenced product information specifies refrigeration at 2–8°C and protection from light.

Keep the ampoules in their original packaging where appropriate. Do not use the medicine after its expiry date or if the ampoule is damaged or the solution does not meet the product's stated appearance requirements. Follow local requirements for pharmaceutical disposal.

Possible adverse effects include:

• Injection-site discomfort
• Flushing or feeling unwell
• Nausea or vomiting
• Changes in blood pressure or heart rate
• Hypersensitivity reactions

Serious allergic reactions, including anaphylaxis, can occur. Administration should take place in a suitable clinical setting where the patient can be observed and emergency treatment is available.

Seek immediate medical attention for difficulty breathing, swelling of the face or throat, widespread hives, collapse or other signs of a severe allergic reaction.

Before administration, the healthcare professional should review the patient's medical history, previous reactions to ACTH-related medicines and current treatments.

Important precautions include:

• Hypersensitivity: Do not use in patients with a known allergy to tetracosactide, relevant ACTH preparations or product ingredients.
• Allergic conditions: Particular caution is necessary in patients with a history of asthma or other allergic conditions because of the risk of serious hypersensitivity reactions.
• Diagnostic interpretation: Certain medicines and clinical conditions can affect cortisol measurements. The treating clinician should review relevant medicines and interpret the results appropriately.
• Clinical monitoring: The medicine should be administered where serious reactions can be recognized and treated promptly.
• Formulation differences: Confirm that the product is short-acting Synacthen and not Synacthen Depot before use.

Refer to the official product leaflet for complete contraindications, warnings and precautions.